



Innovative biomarkers. Smarter healthcare.

Overview

Astute Medical discovers, develops and commercializes novel in-vitro diagnostic biomarker tests. Through its innovative research programs, the Company identifies new biomarkers for acute conditions and diseases, and with clinical collaborators, conducts rigorous clinical trials to validate the biomarkers for routine clinical use. Astute Medical's goal is to create biomarker tests that address previously unmet clinical needs and have the potential to improve patient outcomes.

Recognized by the Wall Street Journal as one of the Top 10 Healthcare Start-ups of 2012, Astute Medical is focused on community- and hospital-acquired conditions lacking adequate diagnosis and risk assessment tools. By responding to unmet needs, the Company aims to create new categories of high value tests.

Astute Medical's first product is a urine test for risk assessment of acute kidney injury (AKI), a perilous condition that is estimated to affect between 7 and 18% of hospital inpatients each year.¹

History

San Diego-based Astute Medical was founded in 2007. Founders Christopher Hibberd and Paul McPherson, Ph.D., previously served on the management team of Biosite Incorporated, playing key roles in the development and commercialization of immunoassay products that changed the practice of cardiovascular medicine. Biosite was acquired by Inverness Medical (now Alere) in 2007 for \$1.7 billion.

Products

Astute Medical's first product is the NEPHROCHECK[®] Test System, an *in vitro* diagnostic device. The Astute Medical NEPHROCHECK[®] Test System is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are ICU patients as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment. The NEPHROCHECK[®] Test System is intended to be used in patients 21 years of age or older.

The NEPHROCHECK[®] Test System consists of the ASTUTE140[®] Meter, NEPHROCHECK[®] Test Kit, NEPHROCHECK[®] Liquid Controls Kit, and NEPHROCHECK[®] Calibration Verification (Cal Vers) Kit.

In the United States, no other *in vitro* diagnostic device is commercially available for the same intended use as the NEPHROCHECK[®] Test.

Patents	For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/US/about/intellectual-property ,
Investors	Astute Medical is a privately held company. Investors include De Novo Ventures, Delphi Ventures, Domain Associates, Kaiser Permanente Ventures, MPM Capital and Ortho-Clinical Diagnostics.
Management	Christopher Hibberd, President & Chief Executive Officer Paul McPherson, Ph.D., Chief Scientific Officer W. Todd Myers, Chief Financial Officer Karin Hughes, Ph.D., Vice President, Clinical & Regulatory Strategy Eric Perreault, Vice President, Sales Mark Mahmood, Vice President, Marketing Philippe Bornibus, Head of Europe
Headquarters	3550 General Atomics Ct. MS 02/641 San Diego, CA 92121, USA
Website	AstuteMedical.com
Media Contact	Nadine Padilla LawPadilla Communications (619) 507-9306 npadilla@lawpadilla.com

Astute Medical®, the AM logo, ASTUTE140®, NEPHROCHECK® and the NEPHROCHECK® logo are registered trademarks of Astute Medical, Inc. in the United States. AKIRISK™ is a trademark of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/about/intellectual-property. PN0105 Rev B 2014/10/14

¹ Lewington AJP, Certa J, Mehta RL. [Raising Awareness of Acute Kidney Injury: A Global Perspective of a Silent Killer](#). *Kidney Int.* 2013;84(3):457-467.